2. Neuronal Signaling Autophagy Apoptosis
  3. Monoamine Oxidase Autophagy Apoptosis
  4. Rasagiline mesylate

Rasagiline mesylate  (Synonyms: (R)-AGN1135 mesylate; TVP1012 mesylate)

Cat. No.: HY-14605 Purity: 99.77%
COA Handling Instructions

Molarity Calculator

Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively. Rasagiline (mesylate) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

For research use only. We do not sell to patients.

Rasagiline mesylate Chemical Structure

Rasagiline mesylate Chemical Structure

CAS No. : 161735-79-1

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in Water
ready for reconstitution
 USD 27 In-stock
Solution
10 mM * 1 mL in Water USD 27 In-stock
Solid
5 mg USD 25 In-stock
10 mg USD 35 In-stock
50 mg USD 60 In-stock
100 mg USD 90 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Rasagiline mesylate:

Rasagiline mesylate Related Antibodies

Top Publications Citing Use of Products

    Rasagiline mesylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Jan 30;9(15):12137-12153.  [Abstract]

    Retinal protection of Rasagiline combined with Idebenone against retinal ischemia-reperfusion (RIR) injury. Western blot analysis for the expression level of brain-derived neurotrophic factor (BDNF) in the whole IR-injured retinas.

    View All Monoamine Oxidase Isoform Specific Products:

    View All Isoforms
    MAO-A MAO-B

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively[1]. Rasagiline (mesylate) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

    IC50 & Target[1]

    rMAO-B

    4.43 nM (IC50)

    rMAO-A

    412 nM (IC50)

    In Vitro

    Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 µM) treatment[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Rasagiline mesylate Related Antibodies

    Cell Viability Assay[2]

    Cell Line: Neuroblastoma SH-SY5Y, and glioblastoma 1242-MG
    Concentration: 0.25 nM
    Incubation Time: 96 hours
    Result: Caused ~60% increase in the cell proliferation rate for SH-SY5Y cells treated with Dexamethasone.
    Caused ~35% increase in cell proliferation rate for 1242-MG cells treated with Dexamethasone.
    In Vivo

    Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: (PLP)-α-synuclein transgenic mice over 6 months of age[3]
    Dosage: Low-(0.8 mg/kg b.w.) and high dose (2.5 mg/kg b. w.)
    Administration: Administered subcutaneously every 24 h for a total period of 4 weeks (from day 1 till day 28 of the experiment).
    Result: Low dose treatment did not show protective efficacy in striatum with number of neurons similar to placebo treated MSA mice. High dose was associated with about 15% rescue of DARPP-32 immunoreactive striatal neurons.
    Low dose treatment had no effect on nigral neuronal loss, but high dose completely protected nigral neurons with numbers comparable to healthy controls.
    Clinical Trial
    Molecular Weight

    267.34

    Formula

    C13H17NO3S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CS(=O)(O)=O.C#CCN[C@H]1C2=CC=CC=C2CC1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    H2O : 25 mg/mL (93.51 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.7406 mL 18.7028 mL 37.4056 mL
    5 mM 0.7481 mL 3.7406 mL 7.4811 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (374.06 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.77%

    COA (251 KB) LCMS (89 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O 1 mM 3.7406 mL 18.7028 mL 37.4056 mL 93.5139 mL
    5 mM 0.7481 mL 3.7406 mL 7.4811 mL 18.7028 mL
    10 mM 0.3741 mL 1.8703 mL 3.7406 mL 9.3514 mL
    15 mM 0.2494 mL 1.2469 mL 2.4937 mL 6.2343 mL
    20 mM 0.1870 mL 0.9351 mL 1.8703 mL 4.6757 mL
    25 mM 0.1496 mL 0.7481 mL 1.4962 mL 3.7406 mL
    30 mM 0.1247 mL 0.6234 mL 1.2469 mL 3.1171 mL
    40 mM 0.0935 mL 0.4676 mL 0.9351 mL 2.3378 mL
    50 mM 0.0748 mL 0.3741 mL 0.7481 mL 1.8703 mL
    60 mM 0.0623 mL 0.3117 mL 0.6234 mL 1.5586 mL
    80 mM 0.0468 mL 0.2338 mL 0.4676 mL 1.1689 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Rasagiline mesylate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Rasagiline161735-79-1(R)-AGN1135TVP1012TVP 1012TVP-1012Monoamine OxidaseAutophagyApoptosisMAOInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Rasagiline mesylate
    Cat. No.:
    HY-14605
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.